Angiotensin II receptor blockers in the treatment of hypertension according to the Polish Society of Hypertension guidelines 2011 Review article
Article Sidebar
Published:
Dec 31, 2011
Keywords:
arterial hypertension, guidelines, angiotensin II receptor blockers
Main Article Content
Abstract
According to the 2007 ESH/ESC guidelines, 2009 reappraisal, also in current Polish Society of Hypertension guidelines, angiotensin II receptor blockers are regarded as a one of the main groups of antihypertensive drugs. Many studies have shown that angiotensin II receptor blockers have a favorable effect on the metabolic profile, vascular changes as well as on renal function. In recent years the emphasis in the treatment of hypertension has been on the individualization of treatment. The article discusses the role of angiotensin II receptor blockers in the treatment of hypertension paying attention to conditions favouring use of this group of drugs.
Article Details
How to Cite
Barylski , M. (2011). Angiotensin II receptor blockers in the treatment of hypertension according to the Polish Society of Hypertension guidelines 2011. Medycyna Faktow (J EBM), 4(4(13), 45-54. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2504
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Knypl K.: Nowe leki hipotensyjne. Cz. I. Ordynator Leków 2002; 2: 18-22.
2. Januszewicz A., Prejbisz A.: Antagoniści receptora angiotensyny II w praktyce klinicznej. Medycyna Praktyczna, Kraków 2009.
3. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
4. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
5. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force dokument. J. Hypertens. 2009; 27: 2121-2158.
6. Blood Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomised trials. BMJ 2008; 336: 1121-1123.
7. Julius S., Kjeldsen S.E., Weber M. et al.: VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
8. Mochizuki S., Dahlof B., Shimizu M. et al.: Jikei Heart Study group: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369(9571): 1431-1439.
9. Sawada T., Yamada H., Dahlof B. et al.: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur. Heart J. 2009; 30: 2461-2469.
10. KYOTO HEART Study [online].
11. Nixon R.M., Müller E., Lowy A., Falvey H.: Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 2009; 63(5): 766-775.
12. Fogari R., Mugellini A., Zoppi A. et al.: Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Current Therapeutic Research 1999; 60(4): 195-206.
13. Januszewicz A.: Nadciśnienie tętnicze. Zarys patogenezy, diagnostyki i leczenia. Medycyna Praktyczna, Kraków 2009.
14. Elliott W.J., Meyer P.M.: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369(9557): 201-207.
15. McMurray J.J., Holman R.R., Haffner S.M. et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 2010; 362: 1477-1490.
16. Somers V.K., White D.P., Amin R. et al.: Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080-1111.
17. Wolf J., Narkiewicz K.: Zespół obturacyjnego bezdechu podczas snu. W: Nadciśnienie tętnicze. Januszewicz A., Januszewicz W., Szczepańska-Sadowska E., Sznajderman M. (red.). Medycyna Praktyczna, Kraków 2007.
18. Januszewicz A., Prejbisz A.: Oporne nadciśnienie tętnicze. Zasady postępowania w praktyce lekarskiej. Via Medica, Gdańsk 2009.
19. Gaddam K., Pimenta E., Thomas S.J. et al.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 2010; 24: 532-537.
20. Pepin J.L., Borel A.L., Baguet J.P. et al.: Hypertension and sleep. European Society of Hypertension Scientific Newsletter 2010; 11: 46.
21. Pepin J.L., Tamisier R., Barone-Rochette G. et al.: Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am. J. Respir. Crit. Care Med. 2010; 182: 954-960.
22. Chobanian A.V.: Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med. 2007; 357: 789-796.
23. Franklin S.S., Gustin W., Wong N.D. et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
24. Januszewicz A.: Nadciśnienie tętnicze. Zarys patogenezy, diagnostyki i leczenia. Medycyna Praktyczna, Kraków 2007.
25. Januszewicz A., Nieszporek T., Prejbisz A. et al.: Leczenie nadciśnienia tętniczego. W: Nadciśnienie tętnicze i diabetologia w pytaniach i odpowiedziach. Januszewicz A., Sieradzki J., Więcek A. (red.). Medycyna Praktyczna, Kraków 2009.
26. Ogihara T., Saruta T., Rakugi H. et al.: Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56: 196-202.
27. Della Chiesa A., Pfiffner D., Meier B. et al.: Sexual activity in hypertensive men. J. Hum. Hypertens. 2003; 17: 515-521.
2. Januszewicz A., Prejbisz A.: Antagoniści receptora angiotensyny II w praktyce klinicznej. Medycyna Praktyczna, Kraków 2009.
3. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15: 55-82.
4. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
5. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force dokument. J. Hypertens. 2009; 27: 2121-2158.
6. Blood Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomised trials. BMJ 2008; 336: 1121-1123.
7. Julius S., Kjeldsen S.E., Weber M. et al.: VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
8. Mochizuki S., Dahlof B., Shimizu M. et al.: Jikei Heart Study group: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369(9571): 1431-1439.
9. Sawada T., Yamada H., Dahlof B. et al.: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur. Heart J. 2009; 30: 2461-2469.
10. KYOTO HEART Study [online].
11. Nixon R.M., Müller E., Lowy A., Falvey H.: Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 2009; 63(5): 766-775.
12. Fogari R., Mugellini A., Zoppi A. et al.: Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Current Therapeutic Research 1999; 60(4): 195-206.
13. Januszewicz A.: Nadciśnienie tętnicze. Zarys patogenezy, diagnostyki i leczenia. Medycyna Praktyczna, Kraków 2009.
14. Elliott W.J., Meyer P.M.: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369(9557): 201-207.
15. McMurray J.J., Holman R.R., Haffner S.M. et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 2010; 362: 1477-1490.
16. Somers V.K., White D.P., Amin R. et al.: Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080-1111.
17. Wolf J., Narkiewicz K.: Zespół obturacyjnego bezdechu podczas snu. W: Nadciśnienie tętnicze. Januszewicz A., Januszewicz W., Szczepańska-Sadowska E., Sznajderman M. (red.). Medycyna Praktyczna, Kraków 2007.
18. Januszewicz A., Prejbisz A.: Oporne nadciśnienie tętnicze. Zasady postępowania w praktyce lekarskiej. Via Medica, Gdańsk 2009.
19. Gaddam K., Pimenta E., Thomas S.J. et al.: Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J. Hum. Hypertens. 2010; 24: 532-537.
20. Pepin J.L., Borel A.L., Baguet J.P. et al.: Hypertension and sleep. European Society of Hypertension Scientific Newsletter 2010; 11: 46.
21. Pepin J.L., Tamisier R., Barone-Rochette G. et al.: Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am. J. Respir. Crit. Care Med. 2010; 182: 954-960.
22. Chobanian A.V.: Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med. 2007; 357: 789-796.
23. Franklin S.S., Gustin W., Wong N.D. et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
24. Januszewicz A.: Nadciśnienie tętnicze. Zarys patogenezy, diagnostyki i leczenia. Medycyna Praktyczna, Kraków 2007.
25. Januszewicz A., Nieszporek T., Prejbisz A. et al.: Leczenie nadciśnienia tętniczego. W: Nadciśnienie tętnicze i diabetologia w pytaniach i odpowiedziach. Januszewicz A., Sieradzki J., Więcek A. (red.). Medycyna Praktyczna, Kraków 2009.
26. Ogihara T., Saruta T., Rakugi H. et al.: Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56: 196-202.
27. Della Chiesa A., Pfiffner D., Meier B. et al.: Sexual activity in hypertensive men. J. Hum. Hypertens. 2003; 17: 515-521.